Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
0.8
2.9
Journals
Diseases
Special Issues
Cancers of the Genitourinary System: Pathophysiology, Modeling, and Treatment
share announcement

Cancers of the Genitourinary System: Pathophysiology, Modeling, and Treatment

A special issue of Diseases (ISSN 2079-9721). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 9 June 2025 | Viewed by 3558

Special Issue Editors

Dr. Hisham Bahmad

E-Mail Website
Guest Editor
The Arkadi M. Rywlin Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
Interests: molecular pathology; cancer stem cells; biomarker research
Special Issues, Collections and Topics in MDPI journals
Dr. Wassim Abou-Kheir

E-Mail Website
Guest Editor
Department of Anatomy, Cell Biology, and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107-2020, Lebanon
Interests: cancer stem cells; solid tumors; biomarkers research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Genitourinary tumors are common neoplasms that include prostate cancer, kidney cancer, bladder cancer, testicular cancer, and cancers of the penis. Each of those cancers is recognized as a heterogeneous disease, and the clinical course is unique to every patient in terms of prognosis and treatment response. With the rapid advancement in the medical field and the wide use of next-generation sequencing techniques to understand cancer, researchers and physicians are moving away from a “one size fits all” strategy in treating the disease to identifying novel biomarkers that can be targeted to specifically treat every patient. Nevertheless, the treatment of most patients with genitourinary cancers requires a multimodality approach that includes surgical intervention, radiation therapy, and chemotherapy.

It is thus crucial to decipher the molecular and cellular mechanisms underlying the initiation and progression of those intractable cancers and accordingly identify the unique biomarkers associated with them to aid in diagnosis and improve prognosis. This approach to the management of genitourinary cancers by applying basic and translational research with bed-side clinical research is the hub for “personalized medicine” in the 21st century and it is an area of great interest to physicians and researchers working in the field, in particular molecular pathologists, and hematology-oncologists. This issue focuses on research and experiences related to cancers of the genitourinary system. This may include deciphering the mechanisms underlying the initiation and progression of genitourinary cancers, including:

pathophysiology; molecular, and cellular mechanism identification of novel cancer biomarker therapeutic targets; improving personalized cancer care using new technologies enhancing cancer diagnoses, management, and outcomes. We invite researchers in molecular pathology, hematology-oncology, genitourinary pathology, stem cells, and other fields of cancer research to submit high-quality reviews related to the issues in this research area.

Dr. Hisham Bahmad
Dr. Wassim Abou-Kheir
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • bladder cancer
  • genitourinary
  • biomarkers
  • therapeutic target
  • personalized medicine
  • targeted therapy
  • genetic aberrations
  • molecular signatures
  • next generation sequencing
  • modeling
  • organoids

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

10 pages, 1655 KiB  
Article
Enzalutamide Prolonged the Duration of Drug Use in Comparison to Abiraterone Acetate and Cabazitaxel after Upfront Docetaxel: A Large Japanese Database Study
by Katsuya Yamaguchi, Takashi Kawahara, Akihito Hashizume, Kimito Ousaka, Koichi Uemura, Yusuke Ito, Hiroki Ito, Kazuhide Makiyama and Hiroji Uemura
Diseases 2024, 12(7), 162; https://doi.org/10.3390/diseases12070162 - 18 Jul 2024
Viewed by 621
Abstract
Introduction: In the United States, a total of 268,490 men were found to have prostate cancer in 2022, thus making it the most common cancer in men, accounting for 27% of all cancers in the male population. Among all cancers in men, it [...] Read more.
Introduction: In the United States, a total of 268,490 men were found to have prostate cancer in 2022, thus making it the most common cancer in men, accounting for 27% of all cancers in the male population. Among all cancers in men, it was the fifth leading cause of death, with 34,500 deaths and a mortality rate of 11%. In 2019, the total number of cases was 94,748, making it the leading cancer in males, accounting for 11% of all male cancers. In terms of mortality, it ranked seventh, with 13,217 deaths and a mortality rate of 1.6%. However, new treatment options for metastatic castration-sensitive prostate cancer (mCSPC) have emerged. Docetaxel has been shown to be effective for both mCSPC and castration-resistant prostate cancer (CRPC). Upfront docetaxel has not been approved in Japan, nor has it been validated in large-scale studies. Furthermore, several agents can be used after docetaxel treatment, but it is unclear which is the most effective. We used a large Japanese health insurance database to determine which agent would be the most effective as a next-line therapy in patients who had received docetaxel. Materials and Methods: We used data from medical institutions using the Diagnosis Procedure Combination (DPC), which provides a comprehensive evaluation of medical classifications. The Medical Data Vision database covers approximately 23% of DPC hospitals in Japan. This study analyzed 2938 patients with mCSPC who received docetaxel, followed by CRPC, between April 2008 and December 2021. The study focused on three agents: enzalutamide, abiraterone acetate, and cabazitaxel. Other agents were excluded due to the small number of patients. The following data were analyzed: age, date of CRPC diagnosis, presence of bone metastasis, drug type, and prognosis. Results: This study included 1997 patients with CRPC after upfront docetaxel therapy for mCSPC (enzalutamide [ENZ] group, n = 998; abiraterone acetate [ABI] group, n = 617; and cabazitaxel [CBZ] group, n = 382). The overall survival (OS) time from drug initiation was 456 days in the enzalutamide group, which was significantly longer than that in the cabazitaxel group (p = 0.017, HR 0.94) (ENZ: ABI p = 0.54, HR 0.94; ABI: CBZ p = 0.14, HR 0.75). OS was also compared for the third-line drug in the group that received enzalutamide as the second-line drug, the group that used abiraterone acetate as the third-line drug (ENZ-ABI group), and the group that used abiraterone acetate as the second-line drug. OS from the start of the third-line drug was compared between the ENZ–ABI group and the ABI–ENZ group, which received enzalutamide as the third-line drug, but showed no significant difference (269 vs. 281 days, p = 0.85; HR 1.03). Conclusion: ENZ was shown to prolong OS relative to cabazitaxel after the cessation of docetaxel. ENZ was associated with a longer duration of drug use than ABI and CBZ. Full article
(This article belongs to the Special Issue Cancers of the Genitourinary System: Pathophysiology, Modeling, and Treatment)
►▼ Show Figures

Figure 1

Other

Jump to: Research

9 pages, 11282 KiB  
Case Report
Renal Cell Carcinoma Presenting as Syncope due to Saddle Pulmonary Tumor Embolism
by Mohamad K. Elajami, Ephraim Mansour, Hisham F. Bahmad, Gerard Chaaya, Steven DeBeer, Robert Poppiti and Yumna Omarzai
Diseases 2022, 10(4), 119; https://doi.org/10.3390/diseases10040119 - 2 Dec 2022
Cited by 3 | Viewed by 2107
Abstract
Pulmonary embolism (PE) is defined as the obstruction of the pulmonary artery or one of its branches by a blood clot, tumor, air, or fat emboli originating elsewhere in the body. A saddle PE occurs when the obstruction affects the bifurcation of the [...] Read more.
Pulmonary embolism (PE) is defined as the obstruction of the pulmonary artery or one of its branches by a blood clot, tumor, air, or fat emboli originating elsewhere in the body. A saddle PE occurs when the obstruction affects the bifurcation of the main pulmonary artery trunk. We present a case of a 46-year-old man who presented to our hospital due to an episode of syncope. Computed tomography angiography (CTA) of the chest showed extensive PE and abdominal CT scan showed a large 8 cm left renal mass with inferior vena cava (IVC) thrombus. Emergent embolectomy, left total nephrectomy, and IVC tumor removal were performed yielding the diagnosis of clear cell renal cell carcinoma (RCC). Interestingly, our patient did not experience any symptoms related to his RCC until the diagnosis of PE due to syncope, and the asymptomatic tumor was found out to be the possible cause of this PE due to the presence of tumor cells constituting the tumor embolus. It is thus recommended to improve the early screening process for RCC. Besides, clinicians should pay attention to patients presenting with uncharacteristic symptoms of RCC who might present with symptoms of saddle PE. Full article
(This article belongs to the Special Issue Cancers of the Genitourinary System: Pathophysiology, Modeling, and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop